Methimazole Dosing in Pregnancy
Methimazole should be used ONLY after the first trimester of pregnancy at the lowest effective dose to maintain maternal free T4 at or slightly above the upper limit of normal, with propylthiouracil preferred during the first trimester due to methimazole's teratogenic risk. 1, 2, 3
Trimester-Specific Approach
First Trimester (Weeks 1-13)
- Avoid methimazole - associated with rare but serious congenital malformations including aplasia cutis, choanal atresia, and esophageal atresia 1
- Use propylthiouracil (PTU) instead during organogenesis
- If patient is already on methimazole and becomes pregnant, switch immediately to PTU upon positive pregnancy test 1
Second and Third Trimesters (Week 14 onwards)
- Switch from PTU to methimazole at the beginning of the second trimester 1, 2
- This switch is recommended because PTU carries risk of potentially fatal hepatotoxicity, which outweighs methimazole's teratogenic risk after organogenesis is complete 1
Specific Dosing Strategy
Starting dose when initiating in second/third trimester:
- Begin with 5-15 mg daily of methimazole 4
- Adjust based on hyperthyroidism severity and individual response
Dose conversion when switching from PTU:
- Use a potency ratio of 20-30:1 (PTU:methimazole) 1
- Example: 300 mg PTU ≈ 10-15 mg methimazole 1
- Check thyroid function 2 weeks after switching, then every 2-4 weeks 2
Treatment Targets and Monitoring
Biochemical goals:
- Keep maternal free T4 at or slightly above the upper limit of normal (non-pregnant reference range) 1, 2
- Alternatively, maintain total T4 at 1.5 times the upper limit of normal 2
- TSH may remain suppressed - do not use as sole guide for dosing 1
Key principle: Use the lowest possible dose to avoid fetal hypothyroidism, as both antithyroid drugs cross the placenta 1
Monitoring frequency:
- Assess thyroid function monthly throughout pregnancy 1
- More frequent monitoring (every 2 weeks initially, then every 2-4 weeks) recommended by some guidelines 2, 4
Critical Caveats
Do NOT use block-replacement therapy (antithyroid drug plus levothyroxine) in pregnancy - this increases fetal hypothyroidism risk 1
Alternative to switching: If concerns about destabilizing thyroid control exist, patient may remain on PTU throughout pregnancy with hepatic enzyme monitoring every 4 weeks, though this approach lacks prospective safety data 1
Dose reduction during pregnancy: Many pregnant women experience improvement in hyperthyroidism as pregnancy progresses due to declining TRAb levels - anticipate need for dose reduction or discontinuation in later pregnancy 1, 3
Postpartum: High risk of relapse after delivery - requires close monitoring at 1,3, and 6 months postpartum 4